Last 12 months
Inside the activity.
7 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 7 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 3, 2023 21:19 UTC |
Pilnik Richard D.Director
|
GrantVoting Common Shares, no par value per share | 55,555 | $1.53 | $84,999.15 |
DisclosureSEC source: 0001235802-23-000001 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,882 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $85,000. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 99,204 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 21:34 UTC |
Giuffre Randall MichaelDirector
|
PurchaseVoting Common Shares, no par value per share | 37,079 | $1.43 | $53,022.97 |
DisclosureSEC source: 0001235802-22-000135 · primary_doc.xml · nonDerivative · entry 2 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,225 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.41 to $1.44, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:34 UTC |
Giuffre Randall MichaelDirector
|
PurchaseVoting Common Shares, no par value per share | 20,000 | $1.40 | $28,000.00 |
DisclosureSEC source: 0001235802-22-000135 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,146 F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 21:55 UTC |
Giuffre Randall MichaelDirector
|
PurchaseVoting Common Shares, no par value per share | 22,574 | $1.40 | $31,603.60 |
DisclosureSEC source: 0001235802-22-000134 · primary_doc.xml · nonDerivative · entry 2 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,146 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.36 to $1.40, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 107,811 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 21:55 UTC |
Giuffre Randall MichaelDirector
|
PurchaseVoting Common Shares, no par value per share | 2,300 | $1.35 | $3,105.00 |
DisclosureSEC source: 0001235802-22-000134 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,572 F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 107,811 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| December 05, 2022 Filed Dec 5, 2022 21:16 UTC |
Pilnik Richard D.Director
|
PurchaseVoting Common Shares, no par value per share | 35,000 | $1.39 | $48,492.50 |
DisclosureSEC source: 0001235802-22-000130 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,327 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3665 to $1.4047, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 43,649 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 20:19 UTC |
Von Koch Thomas10% owner
TomEnterprise AB10% owner
TomEnterprise Private AB10% owner
|
PurchaseCommon Shares | 2,855,847 | $1.24 | $3,526,971.05 |
DisclosureSEC source: 0001567619-22-021344 · doc1.xml · nonDerivative · entry 2 Von Koch Thomas · CIK 0001938915 · 10% owner TomEnterprise AB · CIK 0001887435 · 10% owner TomEqt Private AB · CIK 0001956782 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote 2 Disclosed balance after: 2,855,847 F2 · ownership.nature: These shares are owned directly by TomEqt Private AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEqt Private AB. Thomas Von Koch has the sole power to vote and dispose of these shares. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 20:19 UTC |
Von Koch Thomas10% owner
TomEnterprise AB10% owner
TomEnterprise Private AB10% owner
|
SaleCommon Shares | 2,855,847 | $1.24 | $3,526,971.05 |
DisclosureSEC source: 0001567619-22-021344 · doc1.xml · nonDerivative · entry 1 Von Koch Thomas · CIK 0001938915 · 10% owner TomEnterprise AB · CIK 0001887435 · 10% owner TomEqt Private AB · CIK 0001956782 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote 1 Disclosed balance after: 0 F1 · ownership.nature: These shares were owned directly by TomEnterprise AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEnterprise AB. Thomas Von Koch had the sole power to vote and dispose of these shares. Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 22:11 UTC |
Giuffre Randall MichaelDirector
|
PurchaseVoting Common Shares, no par value per share | 46,133 | $1.20 | $55,359.60 |
DisclosureSEC source: 0001235802-22-000128 · primary_doc.xml · nonDerivative · entry 3 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,453 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.20, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 82,118 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:08 UTC |
Giuffre Randall MichaelDirector
|
PurchaseVoting Common Shares, no par value per share | 819 | $1.19 | $974.61 |
DisclosureSEC source: 0001235802-22-000129 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,272 F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 82,937 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 22:11 UTC |
Giuffre Randall MichaelDirector
|
PurchaseVoting Common Shares, no par value per share | 2,970 | $1.19 | $3,534.30 |
DisclosureSEC source: 0001235802-22-000128 · primary_doc.xml · nonDerivative · entry 2 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,320 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.19, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 82,118 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 22:11 UTC |
Giuffre Randall MichaelDirector
|
PurchaseVoting Common Shares, no par value per share | 18,125 | $1.19 | $21,568.75 |
DisclosureSEC source: 0001235802-22-000128 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,350 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.19, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 82,118 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 01:56 UTC |
Pauls Dietrich JohnDirector · President and CEO
|
PurchaseVoting Common Shares, no par value per share | 20,000 | $1.21 | $24,200.00 |
DisclosureSEC source: 0001235802-22-000121 · primary_doc.xml · nonDerivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.17 to $1.21, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 20:41 UTC |
Daves Julie VanOrsdelSVP Clinical Development Oper.
|
GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001235802-22-000111 · primary_doc.xml · derivative · entry 2 Daves Julie VanOrsdel · CIK 0001945603 · SVP Clinical Development Oper. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Shares · 140,000 shares Expires 2032-09-12 F1 · derivative.exercise_date: This option vests with respect to 35,000 common shares on September 13, 2023 and with respect to the remaining 75% of the common shares in 36 nearly equal monthly installments commencing one month after the one-year anniversary of the grant date. Read SEC document |
| July 08, 2022 Filed Jul 21, 2022 17:06 UTC |
Von Koch Thomas10% owner
TomEnterprise AB10% owner
|
PurchaseCommon Shares | 207,974 | $1.33 | $275,898.31 |
DisclosureSEC source: 0001567619-22-014290 · doc1.xml · nonDerivative · entry 1 Von Koch Thomas · CIK 0001938915 · 10% owner TomEnterprise AB · CIK 0001887435 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,855,827 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.3025 to $1.355, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: These shares are owned directly by TomEnterprise AB and indirectly by Thomas Von Koch in his capacity as the board member and sole owner of TomEnterprise AB. Thomas Von Koch has the sole power to vote and dispose of these shares. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:58 UTC |
Burroughs Amy L.Director
|
GrantStock Option (right to buy) · Derivative | 13,222 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000074 · primary_doc.xml · derivative · entry 2 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,222 Underlying: Common Shares · 13,222 shares Expires 2032-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 21:02 UTC |
Kellen ScottCFO and Secretary
|
GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000075 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Shares · 60,000 shares Expires 2032-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2023 and with respect to the remaining 75% of the underlying common shares in 36 as nearly equal as possible monthly installments commencing on July 1, 2023. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 21:06 UTC |
Pauls Dietrich JohnDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 177,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000076 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,000 Underlying: Common Shares · 177,000 shares Expires 2032-05-31 F2 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2023 and with respect to the remaining 75% of the underlying common shares in 36 as nearly equal as possible monthly installments commencing on July 1, 2023. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:51 UTC |
Giuffre Randall MichaelDirector
|
GrantStock Option (right to buy) · Derivative | 13,222 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000073 · primary_doc.xml · derivative · entry 5 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,222 Underlying: Common Shares · 13,222 shares Expires 2032-05-31 F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:44 UTC |
Parsons James T.Director
|
GrantStock Option (right to buy) · Derivative | 13,222 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000072 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,222 Underlying: Common Shares · 13,222 shares Expires 2032-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:38 UTC |
Pilnik Richard D.Director
|
GrantStock Option (right to buy) · Derivative | 18,510 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000071 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,510 Underlying: Common Shares · 18,510 shares Expires 2032-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:34 UTC |
Semba Charles PaulingDirector
|
GrantStock Option (right to buy) · Derivative | 13,222 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000070 · primary_doc.xml · derivative · entry 2 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,222 Underlying: Common Shares · 13,222 shares Expires 2032-05-31 F1 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:45 UTC |
Cundari Dominic RChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-22-000024 · primary_doc.xml · derivative · entry 3 Cundari Dominic R · CIK 0001907057 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2032-02-01 F2 · derivative.exercise_date: This option vests with respect to 10,000 common shares on May 1, 2022 and with respect to the remaining 75% of the common shares in three nearly equal installments on each of August 1, 2022, November 1, 2022 and February 1, 2023. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:45 UTC |
Cundari Dominic RChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-22-000024 · primary_doc.xml · derivative · entry 2 Cundari Dominic R · CIK 0001907057 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option vests with respect to 31,250 common shares on February 1, 2023 and with respect to the remaining 75% of the common shares in 36 nearly equal monthly installments commencing one month after the one-year anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 3, 2022 21:39 UTC |
Burroughs Amy L.Director
|
GrantVoting Common Shares, no par value per share | 11,182 | $3.58 | $40,031.56 |
DisclosureSEC source: 0001235802-22-000004 · primary_doc.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,132 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $40,000. F2 · balance_after: Includes 11,182 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| January 03, 2022 Filed Jan 3, 2022 21:26 UTC |
Pilnik Richard D.Director
|
GrantVoting Common Shares, no par value per share | 23,762 | $3.58 | $85,067.96 |
DisclosureSEC source: 0001235802-22-000003 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,327 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $85,000. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 43,649 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| January 03, 2022 Filed Jan 3, 2022 21:21 UTC |
Parsons James T.Director
|
GrantVoting Common Shares, no par value per share | 16,773 | $3.58 | $60,047.34 |
DisclosureSEC source: 0001235802-22-000002 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,509 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $60,000. F2 · balance_after: Amount reflects the cancellation of 211 shares underlying deferred share units granted in lieu of Board committee retainers due to a change in Board committee memberships. F3 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 32,409 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| January 03, 2022 Filed Jan 3, 2022 21:09 UTC |
Giuffre Randall MichaelDirector
|
GrantVoting Common Shares, no par value per share | 15,026 | $3.58 | $53,793.08 |
DisclosureSEC source: 0001235802-22-000001 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,225 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $53,750. F2 · balance_after: Amount reflects the cancellation of 422 shares underlying deferred share units granted in lieu of Board committee retainers due to a change in Board committee memberships. F3 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 14,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:57 UTC |
Gruis Kirsten LChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001235802-22-000013 · primary_doc.xml · derivative · entry 2 Gruis Kirsten L · CIK 0001902629 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Shares · 160,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: This option vests with respect to 40,000 common shares on January 3, 2023 and with respect to the remaining 75% of the common shares in 36 nearly equal monthly installments commencing one month after the one-year anniversary of the grant date. Read SEC document |
| September 15, 2021 Filed Sep 15, 2021 20:37 UTC |
ALCORN HARRY W JRSVP, Clinical Operations
|
PurchaseVoting Common Shares, no par value per share | 15,000 | $3.80 | $56,959.50 |
DisclosureSEC source: 0001235802-21-000119 · primary_doc.xml · nonDerivative · entry 1 ALCORN HARRY W JR · CIK 0001186761 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,582 Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 20:10 UTC |
Kellen ScottCFO and Secretary
|
PurchaseVoting Common Shares, no par value per share | 10,000 | $3.15 | $31,463.00 |
DisclosureSEC source: 0001235802-21-000097 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,290 Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 20:27 UTC |
ALCORN HARRY W JRSenior VP, Clinical Operations
|
PurchaseVoting Common Shares, no par value per share | 399 | $3.07 | $1,224.93 |
DisclosureSEC source: 0001235802-21-000099 · primary_doc.xml · nonDerivative · entry 3 ALCORN HARRY W JR · CIK 0001186761 · Senior VP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 399 Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 20:27 UTC |
ALCORN HARRY W JRSenior VP, Clinical Operations
|
PurchaseVoting Common Shares, no par value per share | 322 | $3.06 | $984.93 |
DisclosureSEC source: 0001235802-21-000099 · primary_doc.xml · nonDerivative · entry 2 ALCORN HARRY W JR · CIK 0001186761 · Senior VP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,582 Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 20:27 UTC |
ALCORN HARRY W JRSenior VP, Clinical Operations
|
PurchaseVoting Common Shares, no par value per share | 20,000 | $3.09 | $61,844.00 |
DisclosureSEC source: 0001235802-21-000099 · primary_doc.xml · nonDerivative · entry 1 ALCORN HARRY W JR · CIK 0001186761 · Senior VP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,260 Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 20:19 UTC |
Pauls Dietrich JohnDirector · President and CEO
|
PurchaseVoting Common Shares, no par value per share | 5,000 | $3.14 | $15,700.00 |
DisclosureSEC source: 0001235802-21-000098 · primary_doc.xml · nonDerivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.12 to $3.15, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:11 UTC |
Burroughs Amy L.Director
|
PurchaseVoting Common Shares, no par value per share | 44,950 | $3.15 | $141,592.50 |
DisclosureSEC source: 0001235802-21-000101 · primary_doc.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,950 Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:05 UTC |
Pilnik Richard D.Director
|
PurchaseVoting Common Shares, no par value per share | 12,500 | $3.28 | $41,032.50 |
DisclosureSEC source: 0001235802-21-000100 · primary_doc.xml · nonDerivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,565 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 19,887 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:05 UTC |
Pilnik Richard D.Director
|
PurchaseVoting Common Shares, no par value per share | 2,500 | $3.21 | $8,031.50 |
DisclosureSEC source: 0001235802-21-000100 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,065 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 19,887 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 01:02 UTC |
Kellen ScottCFO and Secretary
|
GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001235802-21-000091 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Shares · 60,000 shares Expires 2031-07-27 F1 · derivative.exercise_date: Vests in sixteen nearly equal quarterly installments over four years. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 01:18 UTC |
Gilman Sydney A.VP, Regulatory Affairs
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001235802-21-000094 · primary_doc.xml · derivative · entry 2 Gilman Sydney A. · CIK 0001793016 · VP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2031-07-27 F1 · derivative.exercise_date: Vests in sixteen nearly equal quarterly installments over four years. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 01:14 UTC |
ALCORN HARRY W JRChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001235802-21-000093 · primary_doc.xml · derivative · entry 2 ALCORN HARRY W JR · CIK 0001186761 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Shares · 60,000 shares Expires 2031-07-27 F1 · derivative.exercise_date: Vests in sixteen nearly equal quarterly installments over four years. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 01:07 UTC |
Pauls Dietrich JohnDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001235802-21-000092 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Shares · 175,000 shares Expires 2031-07-27 F2 · derivative.exercise_date: Vests in sixteen nearly equal quarterly installments over four years. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:35 UTC |
Burroughs Amy L.Director
|
GrantStock Option (right to buy) · Derivative | 18,786 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001235802-21-000079 · primary_doc.xml · derivative · entry 2 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,786 Underlying: Common Shares · 18,786 shares Expires 2031-07-14 F1 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments over three years. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:52 UTC |
Giuffre Randall MichaelDirector
|
GrantStock Option (right to buy) · Derivative | 9,393 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001235802-21-000082 · primary_doc.xml · derivative · entry 5 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,393 Underlying: Common Shares · 9,393 shares Expires 2031-07-14 F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:45 UTC |
Parsons James T.Director
|
GrantStock Option (right to buy) · Derivative | 9,393 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001235802-21-000081 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,393 Underlying: Common Shares · 9,393 shares Expires 2031-07-14 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:40 UTC |
Pilnik Richard D.Director
|
GrantStock Option (right to buy) · Derivative | 13,150 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001235802-21-000080 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,150 Underlying: Common Shares · 13,150 shares Expires 2031-07-14 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:21 UTC |
Semba Charles PaulingDirector
|
GrantStock Option (right to buy) · Derivative | 18,786 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001235802-21-000077 · primary_doc.xml · derivative · entry 2 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,786 Underlying: Common Shares · 18,786 shares Expires 2031-07-14 F1 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments over three years. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 21:33 UTC |
Giuffre Randall MichaelDirector
|
GrantVoting Common Shares, no par value per share | 7,441 | $8.23 | $61,239.43 |
DisclosureSEC source: 0001235802-21-000003 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,029 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $61,250. F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 15,225 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 36,498 voting common shares held by Michael Giuffre and his wife jointly and 60,160 voting common shares held by Michael Giuffre individually. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 21:21 UTC |
Parsons James T.Director
|
GrantVoting Common Shares, no par value per share | 7,745 | $8.23 | $63,741.35 |
DisclosureSEC source: 0001235802-21-000002 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,947 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $63,750. F2 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 15,847 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 21:12 UTC |
Pilnik Richard D.Director
|
GrantVoting Common Shares, no par value per share | 9,719 | $8.23 | $79,987.37 |
DisclosureSEC source: 0001235802-21-000001 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,565 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $80,000. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 19,887 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.